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muscarinic subtypes in perfonnance is still lar-
gely unclear. 
Studies on the effects of specific muscarinic antago-
nists on cognitive perfonnance are rare and studies on 
discriminability even rarer. Most studies have been con-
fined to the effects of the intracerebroventricular (i.c.v.) 
administration of the M 1 antagonist pirenzepine in spatial 
learning tasks (Hagan et al., 1987; Hunter and Roberts, 
1988; Messer et al., 1990; Sala et aL, 1991 ). Andrews et 
al. (1994) recently studied the effects ofpirenzepine, AF-
DX 116 and UH-AH 37 after i.c.v. administration in a 
delayed matching to position (DMTP) task and found 
clear differences in the effects of these selective ligands. 
The M1 receptor antagonist pirenzepine disrupted accu-
racy in a delay-, but not dose-related manner. After in-
jection of pirenzepine into the hippocampus, Messer eta!. 
(1990) also found a decrease in perfonnance on a repre-
sentational memory (non-matching-to-sample, T-maze) 
task Less agreement exists about the consequences of 
antagonising the M2 receptor. Andrews et al. (1994) 
found no disruptions after central injection of the mus-
carinic M2 antagonist AF-DX 116. However, other stu-
dies reported a decrease in representational memory 
perfonnance after hippocampal injection of AF-DX 116 
(Messer et al., 1990). To date, only one study used the M3 
antagonist UH-AH 37: in a delayed matching to position 
task UH-AH 37 was found to disrupt performance se-
verely even in the zero delay condition (Andrews et al., 
1994). 
An alternative method of inducing cholinergic hypo-
function is to deplete the cholinergic neurons of acetyl-
choline. To this end, i.e. v. injections of hemicholinium-3 
(HC3), a high-affinity choline uptake blocker (Russell 
and Macri, 1978), have been used to induce a reversible 
cholinergic depletion. Although at high dosages beha-
vioural disruptions have been reported (Freeman et al., 
1975; Jenden et al., 1977), low doses ofHC3 can induce 
cognitive deficits without accompanying motor distur-
bances (Ridley eta!., 1984, 1987; Hagan et al., 1989; 
Muir et al., 1992; Andrews et al., 1994). 
Given the knowledge that a generalised cholinergic 
blockade results in many non-specific, and probably 
non-cognitive, disruptive effects on behaviour, it is im-
portant to detennine the effects on perfonnance of cho-
linergic depletion as well as of antagonising cholinergic 
receptors. Therefore, the present experiment investigated 
the contribution of the muscarinic cholinergic system to 
task perfonnance, by general and selective antagonism as 
well as by cholinergic depletion. The compounds used 
were chosen because their effects in a DMTP task are 
known and provide a reference for effects on delay-de-
pendent and delay-independent perfonnance. An operant 
two-lever visual discrimination task was chosen, as a 
similar task has proven useful in elucidating the effects 
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of drugs and lesions on performance 
drews and Sahgal, 1984; Andrews and Holtzman, 1988; 
Evenden et al., 1989). These experiments help to estab-
lish whether blockade of a particular muscarinic subtype 
can disrupt visual discrimination in a similar manner to 
that repeatedly observed after general muscarinic block-
ade (e.g. Andrews et a/., 1992), cholinergic lesions (e.g. 
Dunnett et al., 1991) or cholinergic depletion (e.g. Muir 
et al., 1992). 
MATERIALS AND METHODS 
Subjects and surgery 
Subjects were male Long-Evans rats (supplied by HAR-
LAN, Zeist), weighing approximately 275 gat the begin-
ning of the experiment. Rats were individually housed in 
standard Makrolon cages and maintained on a 12: 12 h 
light: dark cycle, with lights on at 08.00 h. A restricted 
feeding schedule (down to 90% of free-feeding weight) 
was introduced three days before training, but access to 
tap water was free at all times. After training the animals 
to criterion (see below) animals were allowed to free-feed 
for three days before surgery. Each rat was implanted 
under anaesthesia (Nembutal, 60 mg/kg i.p.) with a stain-
less steel guide cannula (Organon B.V, The Netherlands), 
aimed at the right lateral ventricle: coordinates from 
Bregma, AP= -0.8 mm, Lat= - 1.5 mm, 
HV = 3.0 mm (Paxinos and Watson, 1982). I.c.v. injec-
tions of dye histologically verified correct cannula posi-
tioning post mortem. Food deprivation was reinstated one 
week after surgery. 
Apparatus 
Eight operant chambers (L 27 x W 25 x H 24 em), 
equipped with two retractable levers, a centrally placed 
food tray and pellet dispenser (delivering 45 mg pellets), 
red house light, and two cue light displays above the 
levers, were connected to Skinner Box Controllers and 
controlled by an Apple Macintosh SE 30. Boxes, con-
trollers and software were developed by the Electronic 
and Computer Engineering Department arid the Mechan-
ical Engineering Department of the Psychological Lab-
oratory, University of Nijmegen. The cue light consisted 
of 64 green LEDs (PD 1167, Siemens), together forming 
a 25.4 mm square light. 
Visual discrimination learning 
Rats were initially trained to press the levers on an FR 1 
schedule of food reinforcement using an autoshaping 
schedule. Subsequently, both levers were pennanently 
available in the chamber; when a cue light was presented, 
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FIG. 1 Effects of the M1 antagonist pirenzepine, the M2 antagonist AF-DX 116, and the M3 antago-
nist UH-AH 37 on visual discrimination performance in the rat. Doses (in 11g per rat i.c.v.) are 
represented on the horizontal axis. Left panels: effects on accuracy as measured by percentage 
correct responses; centre panels: mean number of missed trials from a session of 100 trials; right 
panels: mean latency to respond in seconds. Values are means and standard deviations; * indicates 
a significant difference from vehicle (0). 
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accuracy is affected before speed or frequency of re-
sponding (e.g. Andrews et al., 1994; Bymaster et a/., 
1993; Hagan et al., 1987). An earlier study had shown 
that pirenzepine was able to disrupt performance in the 
DMTP task at a 10-fo1d lower dose without correspond-
ing effects on ability to respond (Andrews et a/., 1994 ). It 
should be noted that the effects ofpirenzepine in both this 
and the DMTP study are small and indicate some caution 
in ascribing a major role forM 1 receptors in memory and 
attention without substantially more data than is available 
at the current time. 
The effects of AF-DX 116 were surprising; apart from 
greater M2 activity in vitro, AF-DX 116 is rather less 
potent at other muscarinic receptors than the other ana-
logues tested (Doods et al., 1994). To date, M2 antago-
nists have been reported to have no effect or a facilitating 
effect on mnemonic performance in rats (Andrews et al., 
1994; Doods et al., 1993); there are no comparable stu-
dies on visual attention or discrimination. Messer et al. 
(1990) reported a decrement in performance following 
intrahippocampal injections of AF-DX 116 in their repre-
sentational memory task. In the same experiment, piren-
zepine was observed to disrupt memory at lower doses 
and the difference between the effective doses of the two 
compounds appeared to reflect relative potencies at the 
M1 receptor. A similar explanation is not possible here: 
the effect of AF-DX 116 was greater than that ofpiren-
zepine, and contrasts strongly with results obtained using 
similar doses and strain of rats in a DMTP task (Andrews 
et al., 1994). It seems unlikely that AF-DX 116 could 
exert a large and selective effect on visual discrimination 
performance without causing some decrements in com-
plex and demanding procedures such as DMTP. Thus, 
there is no immediately convincing explanation for these 
large discrepancies and further research is required to 
evaluate all the possibilities. 
Of the three antagonists tested i.c.v., UH-AH 37 had 
the most potent effects on performance. The differences 
between pirenzepine and its close structural analogue 
UH-AH 37 are potentially the most interesting. Pirenze-
pine had only a small effect on accuracy at the highest 
dose, whereas UH-AH 37 had a greater effect on accu-
racy at both 10 and 32 f.l.g doses and suppressed respond-
ing more than all other compounds apart from 
scopolamine. 
The present data are consistent with a previous study 
involving DMTP, indicating a more potent disruption of 
performance by UH-AH 37 than by pirenzepine (An-
drews et al., 1994). A number of studies have indicated 
that in functional assays pirenzepine and UH-AH 37 dif-
fer mostly in their effects on mediated responses 
(Hagan et al., 1988; Kilbinger et al., 1991; Wess et al., 
1991; Ten Berge et al., 1993; Doods et al., 1994). Never-
theless, other differences between pirenzepine and UH-
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AH 37 in both binding and functional essays, re11tec1mg 
activity at other muscarinic subtypes, have also been re-
ported (Eberlein et al., 1989; Wess et al., 1991; Bognar et 
al., 1992; Doods et al., 1994). Therefore, it is debatable 
whether the difference between the effects ofUH-AH 37 
and pirenzepine can be solely attributed to the differences 
in activity at M1 and M3 receptors. UH-AH 37 also shows 
high affinity for M4 receptors (Doods et al., 1994) and 
despite the fact that these receptors are much more pre-
valent in the brain than M3 (but not M1) receptors (Levey, 
1993 ), little is known concerning their pharmacology. To 
resolve the question as to the relative importance of M3 
receptors in performance in the visual discrimination task 
requires the use of a more selective M 1 antagonist than 
pirenzepine and a more selective M3 antagonist than UH-
AH 37. 
The effects of all compounds apart from scopolamine 
can be assumed to be strictly centrally mediated. Despite 
the possible involvement of peripheral cholinergic recep-
tor antagonism in the action of scopolamine, the simila-
rities in effects to the other compounds indicate a strong 
influence of central muscarinic receptors on performance. 
Dissociating the peripheral and central effects of scopo-
lamine has proven to difficult: qualitatively similar effects 
of methyl scopolamine and scopolamine on operant per-
formance are often reported: e.g. Andrews et ai., 1992; 
Dunnett et al., 1989; Hudzik and Wenger, 1993 (see 
Moore et al. (1992) for a discussion). However, the great-
er suppression of overall responding in the scopolamine-
treated animals may be due to the additional antagonism 
of peripheral cholinergic receptors. Accordingly, it is of 
interest that scopolamine significantly affected frequency 
to respond at a lower dose than accuracy, whereas UH-
AH 37 had a significant effect on accuracy at a lower dose 
than on trials completed. 
Although HC3 has been available for more than 30 
years, the number of studies involving complex beha-
viours remains smalL In studies to date the active dose 
range appears to be 1-5 11g per rat i.c.v.; doses higher 
than this do not have any greater effects on acetylcholine 
levels in the brain (Freeman et al., 1979). Within this 
range, effects are seen on acquisition of a lever press 
(Andrews, unpublished observations), on spatial memory 
as measured in the swim maze, and in DMTP tasks (Ha-
gan et al., 1989; Andrews et al., 1994), and on aspects of 
visual attention as measured here and in a serial reaction 
time task (Muir et al., 1992). Earlier studies using mon-
keys have suggested a separation of mnemonic and per-
ceptual or motor effects (Ridley et al., 1984, 1987). The 
effects here and in the earlier DMTP study (Andrews et 
al., 1994) may indicate that, although the effects on at-
tentional and perceptual factors are close, they are per-
haps separable: 1 and 5 Jlg HC3 had similar effects on 
DMTP, but only 5 11g had any effect on the current task. 
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